Buy Merck Stock -

Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings

Merck maintains a strong financial foundation, supported by its dominance in the global oncology market. Approximately $110.03 as of April 28, 2026. buy merck stock

Trading at a forward P/E of roughly 15.1 , which is often lower than industry peers like Pfizer, suggesting a potential value play. Some discounted cash flow (DCF) models estimate its intrinsic value significantly higher, near $214.74 . Merck & Co Inc (MRK) 3.36% since Jan 3, 2026 Closed: 23:00 • Disclaimer After hours: 02:35 Apr 28, 2026 Open111.52 Mkt cap$271.76B USD 52-wk high125.14 High111.91 P/E ratio15.11 52-wk low73.31 Div yield3.09% The "Keytruda" Factor: Growth vs. Risk Buy, Sell or Hold MRK Stock: Key Factors

Currently yielding about 3.09% , with a reliable history of increases. The quarterly dividend was recently set at $0.85 per share . Some discounted cash flow (DCF) models estimate its

Buying in 2026 involves balancing the stability of its current oncology-driven cash flow against a looming 2028 "patent cliff" for its top-selling drug, Keytruda . As of late April 2026, the stock is viewed by many analysts as a buy or moderate buy , often considered undervalued by intrinsic cash-flow models despite near-term earnings headwinds. Market Position and Financial Snapshot